Head-to-head evidence
177Lu-RAD204 vs Atezolizumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: PD-L1 · full Non-Small Cell Lung Cancer pipeline
177Lu-RAD204
Developed by Radiopharm Theranostics, Ltd
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2027 · NCT06305962 (registry estimate)
Atezolizumab
Marketed by Roche
NCT02008227 · Phase 3 · completed
This large randomized, active-controlled Phase 3 trial (1225 patients) compared atezolizumab to docetaxel in advanced NSCLC. The primary endpoint was overall survival, a hard clinical endpoint, and it was met: median OS 13.8 months for atezolizumab vs 9.6 months for docetaxel, HR 0.73 (95% CI 0.62-0.87), p=0.0003. The trial was not blinded (open-label), so despite the robust randomized design and positive result, the evidence is graded moderate rather than strong.
Next expected readout: November 2026 · NCT04958811 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: 177Lu-RAD204's landscape · Atezolizumab's landscape